Abstract
Research question
Could in-vitro action of follicles and fresh tissue autotransplantation without tissue
culture (drug-free IVA) be useful in patients with primary ovarian insufficiency (POI)?
Design
Prospective observational cohort study in a tertiary university hospital. Drug-Free
IVA was carried out in 14 women with POI with a median age of 33 years (29–36 years),
median length of amenorrhoea of 1.5 years (1–11 years), median FSH levels 69.2 mIU/ml
(36.9–82.8 mIU/ml) and anti-Müllerian hormone of 0.02 ng/ml (0.01–0.1 ng/ml). The
surgical procedure included laparoscopic removal of ovarian cortex, fragmentation
of tissue and autografting. Human menopausal gonadotrophin (HMG) was started immediately
after surgery.
Results
Follicle development was detected in seven out of the 14 patients, and five women
achieved successful oocyte retrieval. In six women, HCG was administered in 10 cycles.
Six embryo transfers were carried out in five women resulting in four pregnancies;
a clinical pregnancy rate of four in seven oocyte retrievals and four in six embryo
transfers.
Conclusions
Drug-free IVA could be a useful therapeutic option for patients with POI, leading
to successful IVF outcomes.
KEYWORDS
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Reproductive BioMedicine OnlineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial.BMJ. 2004; 328: 192https://doi.org/10.1136/bmj.328.7433.192
- Premature ovarian failure: predictability of intermittent ovarian function and response to ovulation induction agents.Curr. Opin. Obstet. Gynecol. 2008; 20: 416-420https://doi.org/10.1097/GCO.0b013e328306a06b
- Resumption of ovarian function and pregnancies in patients with premature ovarian failure.J. Clin. Endocrinol. Metab. 2011; 96: 3864-3872https://doi.org/10.1210/jc.2011-1038
- Retrospective analysis of reproductive outcomes in women with primary ovarian insufficiency showing intermittent follicular development.Reprod. Biomed. Online. 2016; 32: 427-433https://doi.org/10.1016/j.rbmo.2015.12.001
- Primary ovarian insufficiency.Lancet. 2010; 376: 911-921https://doi.org/10.1016/S0140-6736(10)60355-8
- Hormone replacement therapy and successful pregnancy in a patient with premature ovarian failure.Gynecol. Endocrinol. 2009; 25: 769-772https://doi.org/10.3109/09513590903004126
- IVF outcome in patients with orthotopically transplanted ovarian tissue.Hum. Reprod. 2009; 24: 2778-2787https://doi.org/10.1093/humrep/dep289
- ESHRE Guideline: management of women with premature ovarian insufficiency.Hum. Reprod. 2016; 31: 926-937https://doi.org/10.1093/humrep/dew027
- Pregnancy After Orthotopic Ovarian Tissue Transplantation Using N-Hexyl-2-Cyanoacrylate as A Tissue Adhesive.Trends in Transplant. 2017; 11: 5-12https://doi.org/10.15761/TiT.1000242
- Pregnancy after drug-free in vitro activation of follicles and fresh tissue autotransplantation in primary ovarian insufficiency patient: a case report and literature review.J. Ovarian. Res. 2018; 11: 2-5https://doi.org/10.1186/s13048-018-0447-3
- Laparoscopic drilling by diathermy laser for ovulation induction in anovulatory polycystic ovary syndrome.Cochrane Database Syst. Rev. 2012; (Cd001122)https://doi.org/10.1002/14651858.CD001122.pub4
- Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation.Hum. Reprod. 2018; 33: 1705-1714
- Hippo signaling: growth control and beyond.Development. 2011; 138: 9-22https://doi.org/10.1242/dev.045500
- Why does ovarian surgery in PCOS help? Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome.Hum. Reprod. Update. 2007; 13: 249-264https://doi.org/10.1093/humupd/dml058
- Mammalian Hippo signaling: a kinase network regulated by protein-protein interactions.Biochem. Soc. Trans. 2012; 40: 124-128https://doi.org/10.1042/BST20110619
- Intraovarian control of early folliculogenesis.Endocr. Rev. 2015; 36: 1-24https://doi.org/10.1210/er.2015.36.issue-1.edboard
- Tensegrity: the architectural basis of cellular mechanotransduction.Annu. Rev. Physiol. 1997; 59: 575-599https://doi.org/10.1146/annurev.physiol.59.1.575
- Hipposignaling disruption and Akt stimulation of ovarian follicles for infertility treatment.Proc. Natl. Acad. Sci. USA. 2013; 110: 17474-17479https://doi.org/10.1073/pnas.1312830110
- Disorganization of the germ cell pool leads to primary ovarian insufficiency.Reproduction. 2017; 153: 205-213https://doi.org/10.1530/REP-17-0015
- Regulation of follicle growth through hormonal factors and mechanical cues mediated by hippo signaling pathway.Syst. Biol. Reprod. Med. 2018; 64: 3-11https://doi.org/10.1080/19396368.2017.1411990
- Assisted conception following poor ovarian response to gonadotrophin stimulation.Br. J. Obstet. Gynaecol. 1997; 104: 521-527https://doi.org/10.1111/j.1471-0528.1997.tb 11525-x
- Unexpected pregnancy during hormone-replacement therapy in a woman with elevated follicle stimulating hormone levels and amenorrhea.Gynecol. Endocrinol. 1999; 13: 89-92https://doi.org/10.3109/09513599909167538
- Activation of dormant ovarian follicles to generate mature eggs.Proc. Natl. Acad. Sci. USA. 2010; 107https://doi.org/10.1073/pnas.1001198107
- Hippo signaling in the ovary an polycystic ovarian syndrome.J. Assist. Reprod. Genet. 2018; 35: 1763-1771https://doi.org/10.1007/s10815-018-1235-0
- Current concepts in premature ovarian insufficiency.Womens Health. 2015; 11: 169-182https://doi.org/10.2217/whe.14.82
- Inhibition of PTEN activates bovine non-growing follicles in vitro but increases DNA damage and reduces DNA repair response.Hum. Reprod. 2019; 34: 297-307https://doi.org/10.1093/humrep/dey354
- Follicle- stimulating hormone enhances the development of preantral follicles in juvenile rats.Biol. Reprod. 1997; 57: 990-998https://doi.org/10.1095/biolreprod57.5.990
- Clinical practice. Primary ovarian insufficiency.N. Engl. J. Med. 2009; 360: 606-614https://doi.org/10.1056/NEJMcp0808697
- A preliminary report on oocyte donation extending reproductive potential to women over 40.N. Engl. J. Med. 1990; 323: 1157-1160https://doi.org/10.1056/NEJM199010253231702
- Biomechanics and mechanical signaling in the ovary: a systematic review.J. Assist. Reprod. Genet. 2018; 35: 1135-1148https://doi.org/10.1007/s10815-018-1180-y
- Occult form of premature ovarian insufficiency.Gynecol. Endocrinol. 2016; 32: 30-32https://doi.org/10.1080/09513590.2016.1232676
- Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency.Hum. Reprod. 2015; 30: 608-615https://doi.org/10.1093/humrep/deu353
- In vitro activation: A Dip Into the primordial follicle pool ?.J. Clin. Endocrinol. Metab. 2016; 101: 3568-3570https://doi.org/10.1210/jc.2016-2837
- In vitro activation of follicles and fresh tissue autotransplantation in primary ovarian insufficiency patients.J. Clin. Endocrinol. Metab. 2016; 101: 4405-4412https://doi.org/10.1210/jc.2016-1589
Biography
Janisse Ferreri, MD, from Universidade do Brasil, completed her Human Reproduction Master's Degree at Universitat Autonoma de Barcelona, Spain. In 2017, Dr Ferreri received a grant for her research in ovarian in-vitro activation, and she continues her clinical practice at the Reproductive Unit, Hospital Clinic de Barcelona, Spain.Article Info
Publication History
Published online: November 28, 2019
Accepted:
November 14,
2019
Received in revised form:
November 3,
2019
Received:
June 11,
2019
Declaration: This study was supported by the grant ‘Premi Fi de Residencia Emili Letang 201’h from the Hospital Clinic of Barcelona: 398-37-250,777 PFR 2017. The authors report no financial or commercial conflicts of interest.Identification
Copyright
© 2019 Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.
